Posted by & filed under Governments & Regulators, Growth & Valuation, Industry Analysis, Management Issues.

Description: After the hit taken by Mylan Inc. last week for its sixfold increase in the price of the lifesaving EpiPen, Umer Raffat, an analyst at Evercore ISI, has been receiving a certain request: Investors want to know which companies are making similar moves.

Source: MarketWatch.com

Date: Sep 02, 2016

Link: http://www.marketwatch.com/story/mylans-epipen-caught-the-full-force-of-drug-price-outrage-because-it-was-the-perfect-target-not-because-it-was-the-only-one-2016-08-31?siteid=nwtwk

Questions for Discussions:

  • What does the report say about the industry and pricing strategies?
  • Why do you think the industry is able to raise prices as it does?
  • What does this environment mean for investors?

Leave a Reply

Your email address will not be published.